Leerink Partnrs Issues Negative Outlook for TMO Earnings

Thermo Fisher Scientific Inc. (NYSE:TMO) – Investment analysts at Leerink Partnrs cut their Q1 2025 earnings per share (EPS) estimates for shares of Thermo Fisher Scientific in a research note issued on Wednesday, December 11th. Leerink Partnrs analyst P. Souda now forecasts that the medical research company will earn $5.43 per share for the quarter, down from their prior forecast of $5.59. The consensus estimate for Thermo Fisher Scientific’s current full-year earnings is $21.68 per share. Leerink Partnrs also issued estimates for Thermo Fisher Scientific’s Q2 2025 earnings at $5.62 EPS, Q3 2025 earnings at $5.64 EPS, Q4 2025 earnings at $6.49 EPS, FY2025 earnings at $23.18 EPS and FY2026 earnings at $25.36 EPS.

Several other analysts have also recently weighed in on the company. Royal Bank of Canada lowered their price target on Thermo Fisher Scientific from $767.00 to $718.00 and set an “outperform” rating on the stock in a report on Thursday, October 24th. Wells Fargo & Company lowered their target price on shares of Thermo Fisher Scientific from $670.00 to $660.00 and set an “overweight” rating on the stock in a research note on Thursday, October 24th. TD Cowen boosted their price target on shares of Thermo Fisher Scientific from $656.00 to $686.00 in a research note on Tuesday, October 22nd. Barclays lowered their price objective on shares of Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating on the stock in a research report on Wednesday, October 23rd. Finally, Stephens started coverage on Thermo Fisher Scientific in a research note on Tuesday, October 1st. They issued an “overweight” rating and a $680.00 target price on the stock. Four investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and a consensus price target of $652.30.

Thermo Fisher Scientific Stock Performance

Shares of TMO opened at $530.26 on Monday. The stock’s 50-day simple moving average is $549.02 and its 200 day simple moving average is $573.54. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.26 and a current ratio of 1.63. Thermo Fisher Scientific has a 52-week low of $493.30 and a 52-week high of $627.88. The stock has a market capitalization of $202.82 billion, a price-to-earnings ratio of 33.25, a price-to-earnings-growth ratio of 3.54 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.25 by $0.03. The business had revenue of $10.60 billion during the quarter, compared to the consensus estimate of $10.63 billion. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The firm’s quarterly revenue was up .2% compared to the same quarter last year. During the same quarter last year, the company posted $5.69 earnings per share.

Thermo Fisher Scientific declared that its Board of Directors has initiated a share buyback plan on Friday, November 15th that authorizes the company to buyback $4.00 billion in shares. This buyback authorization authorizes the medical research company to reacquire up to 2% of its stock through open market purchases. Stock buyback plans are usually a sign that the company’s management believes its shares are undervalued.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, January 15th. Investors of record on Friday, December 13th will be issued a dividend of $0.39 per share. The ex-dividend date is Friday, December 13th. This represents a $1.56 dividend on an annualized basis and a yield of 0.29%. Thermo Fisher Scientific’s dividend payout ratio is currently 9.78%.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, October 25th. The stock was sold at an average price of $560.16, for a total value of $168,048.00. Following the sale, the executive vice president now directly owns 16,663 shares in the company, valued at approximately $9,333,946.08. This trade represents a 1.77 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, October 28th. The shares were sold at an average price of $554.29, for a total value of $5,542,900.00. Following the transaction, the chief executive officer now owns 121,192 shares of the company’s stock, valued at approximately $67,175,513.68. This represents a 7.62 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 47,150 shares of company stock valued at $25,954,465 in the last quarter. Company insiders own 0.34% of the company’s stock.

Hedge Funds Weigh In On Thermo Fisher Scientific

Hedge funds and other institutional investors have recently modified their holdings of the stock. Raymond James Financial Services Advisors Inc. grew its stake in Thermo Fisher Scientific by 2.9% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 92,057 shares of the medical research company’s stock worth $50,908,000 after purchasing an additional 2,591 shares during the period. Cidel Asset Management Inc. lifted its position in Thermo Fisher Scientific by 3.2% during the 2nd quarter. Cidel Asset Management Inc. now owns 1,222 shares of the medical research company’s stock valued at $676,000 after acquiring an additional 38 shares during the period. Hobbs Group Advisors LLC bought a new stake in Thermo Fisher Scientific during the second quarter worth about $76,000. Focus Financial Network Inc. increased its stake in shares of Thermo Fisher Scientific by 24.9% during the second quarter. Focus Financial Network Inc. now owns 3,918 shares of the medical research company’s stock valued at $2,175,000 after purchasing an additional 780 shares in the last quarter. Finally, Graybill Wealth Management LTD. lifted its holdings in shares of Thermo Fisher Scientific by 0.3% during the second quarter. Graybill Wealth Management LTD. now owns 12,283 shares of the medical research company’s stock valued at $6,793,000 after purchasing an additional 32 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.